Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene-Reference-Cited by-同舟云学术

Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene

Published:2015-08-18 Issue:8 Volume:10 Page:e0135441
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Bertoli Diego,Serana Federico,Sottini Alessandra,Cordioli Cinzia,Maimone Davide,Amato Maria Pia,Centonze Diego,Florio Ciro,Puma Elisa,Capra Ruggero,Imberti Luisa

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference39 articles.

1. Interferon-β-1b: a review of its use in multiple sclerosis;GL Plosker;CNS Drugs,2011

2. US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles;SL Galetta;CNS Drugs,2005

3. Side effect profile of interferon beta-1b in MS: results of an open label trial;LK Neilley;Neurology,1996

4. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis;Lancet,1998

5. Time of interferon-beta 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients;T Kümpfel;Mult Scler,2007

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interleukin 6 SNP rs1818879 Regulates Radiological and Inflammatory Activity in Multiple Sclerosis;Genes;2022-05-17

2. Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study;PLOS ONE;2017-07-07

3. Interleukin 6 promoter 174 G/C polymorphisms in acute ischemic stroke: G allele is protective but not associated with IL-6 levels or stroke outcome;Journal of Neuroimmunology;2016-04